Bioscibex secures CHF 150,000 from Venture Kick to streamline biopharma manufacturing
29.09.2025
EPFL spin-off Bioscibex, a biotech hardware startup developing advanced single-use bioreactors, has secured CHF 150,000 in funding from Venture Kick. The financing will accelerate the commercialization of its first product, Swingo, designed to simplify and automate cell culture, making biologic therapies more accessible.
 |
 |
Biologics have revolutionized the treatment of cancer, autoimmune disorders, and other severe diseases. Yet their high cost—driven largely by complex and expensive manufacturing—still limits patient access. Current bioreactor systems rely on labor-intensive, multi-step processes that increase costs, slow development timelines, and raise the risk of contamination.
Bioscibex is changing this with Swingo, a single-use bioreactor that simplifies the traditional seven-step cell culture process into just two steps. This streamlined approach reduces manual handling, lowers contamination risks, and cuts operational costs. With a scalable working volume from 30 mL to 30 L, Swingo supports applications ranging from R&D to full-scale manufacturing. Unlike conventional systems, it combines simplicity and automation in a single platform, giving biopharma companies a faster, more flexible, and capital-efficient path to drug development and production.
The EPFL spin-off operates in the global shaking incubators and bioreactors market, valued at USD 8 billion, where key players include Cytiva, Sartorius, Thermo Fisher, and Kuhner Shaker. Within this market, Swingo addresses a total addressable segment of roughly USD 1 billion. Target customers include biopharmaceutical companies, contract manufacturing organizations, and biotech firms. The CHF 150,000 from Venture Kick will help secure the first sales to demonstration customers.
Founded in 2024 as an EPFL spin-off, Bioscibex is led by Chloé Albietz (CEO) and Francois Carruzzo (CTO), who bring extensive industry expertise in biopharmaceutical engineering. The company has already raised CHF 1 million in funding and attracted early interest from leading pharmaceutical manufacturers. With the Venture Kick support, Bioscibex is preparing for its commercial launch in Q2 2026, aiming to set a new standard in bioreactor technology.
“Bioscibex is proud to have been supported by Venture Kick, a symbol of quality and credibility in the Swiss startup ecosystem and beyond,” highlighted CEO Chloé Albietz. “Bioscibex benefits from not only early-stage funding but also strategic guidance and connections to investors and industry leaders.”
Bioscibex Co-Founders: CEO Chloé Albietz and CTO François Carruzzo
Bioscibex is changing this with Swingo, a single-use bioreactor that simplifies the traditional seven-step cell culture process into just two steps. This streamlined approach reduces manual handling, lowers contamination risks, and cuts operational costs. With a scalable working volume from 30 mL to 30 L, Swingo supports applications ranging from R&D to full-scale manufacturing. Unlike conventional systems, it combines simplicity and automation in a single platform, giving biopharma companies a faster, more flexible, and capital-efficient path to drug development and production.
The EPFL spin-off operates in the global shaking incubators and bioreactors market, valued at USD 8 billion, where key players include Cytiva, Sartorius, Thermo Fisher, and Kuhner Shaker. Within this market, Swingo addresses a total addressable segment of roughly USD 1 billion. Target customers include biopharmaceutical companies, contract manufacturing organizations, and biotech firms. The CHF 150,000 from Venture Kick will help secure the first sales to demonstration customers.
Founded in 2024 as an EPFL spin-off, Bioscibex is led by Chloé Albietz (CEO) and Francois Carruzzo (CTO), who bring extensive industry expertise in biopharmaceutical engineering. The company has already raised CHF 1 million in funding and attracted early interest from leading pharmaceutical manufacturers. With the Venture Kick support, Bioscibex is preparing for its commercial launch in Q2 2026, aiming to set a new standard in bioreactor technology.
“Bioscibex is proud to have been supported by Venture Kick, a symbol of quality and credibility in the Swiss startup ecosystem and beyond,” highlighted CEO Chloé Albietz. “Bioscibex benefits from not only early-stage funding but also strategic guidance and connections to investors and industry leaders.”
Bioscibex Co-Founders: CEO Chloé Albietz and CTO François Carruzzo